The effectiveness of the Hybrid Closed Loop (HCL) system has been demonstrated in randomized controlled studies. This extensive national study was conducted to assess the initiation process, follow-up modalities, and the metabolic effectiveness of HCL during real-life use, following six and twelve months of continuous usage.
Methods: All adult patients who began HCL therapy between January 1st and December 31st, 2022, were included from 48 centers, irrespective of the specific HCL model employed. Clinical, continuous glucose monitoring (CGM), and HbA1c data were gathered at the initiation of HCL therapy and subsequently every 6 months. We also documented the approach healthcare professionals took when educating patients during follow-up. In this report, we present the 6-month and 12-month follow-up results for adult patients in the study.
Results: A total of 2156 adults patients were included; baseline characteristics are presented in Table 1. Metabolic evolution at 6 months ((n=1993) and at 12 months (n=1143) are presented in Table 2. At 12 months, 3.2% have stopped the HCL.
Conclusions: HCL has shown remarkable effectiveness in real-life scenarios, enabling the achievement of time in range goals and a significant reduction in severe hypoglycemic events after a 12-month follow-up. Only a small number of patients discontinued the use of HCL.
J. Riveline: Board Member; Abbott, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Inc., Insulet Corporation, Air Liquide, AstraZeneca. J. Julla: Speaker's Bureau; Lilly Diabetes, Novo Nordisk. Board Member; Sanofi. M. Joubert: Consultant; Abbott, Medtronic, Dexcom, Inc. S. Lablanche: None. E. Renard: None. J. Gautier: Board Member; Sanofi. Other Relationship; Sanofi. Speaker's Bureau; AstraZeneca, Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Pfizer Inc.
